| アブストラクト | BACKGROUND: Adverse drug reactions (ADRs) in the pediatric population may differ in types and frequencies compared to other populations. Respective studies analyzing ADR reports referring to children have already been performed for certain countries. However, differences in drug prescriptions, among others, complicate the transferability of the results from other countries to Germany or were rarely considered. Hence, the first aim of our study was to analyze the drugs and ADRs reported most frequently in ADR reports from Germany referring to children contained in the European ADR database (EudraVigilance). The second aim was to set the number of ADR reports in relation to the number of drug prescriptions. These were provided by the Research Institute for Ambulatory Health Care in Germany. METHODS: For patients aged 0-17 years 20,854 spontaneous ADR reports were received between 01/01/2000-28/2/2019. The drugs and ADRs reported most frequently were identified. Stratified analyses with regard to age, sex and drugs used "off-label" were performed. Reporting rates (number of ADR reports/number of drug prescriptions) were calculated. RESULTS: Methylphenidate (5.5%), ibuprofen (2.3%), and palivizumab (2.0%) were most frequently reported as suspected. If related to the number of drug prescriptions, the ranking changed (palivizumab, methylphenidate, ibuprofen). Irrespective of the applied drugs, vomiting (5.4%), urticaria (4.6%) and dyspnea (4.2%) were the ADRs reported most frequently. For children aged 0-1 year, drugs for the treatment of nervous system disorders and foetal exposure during pregnancy were most commonly reported. In contrast, methylphenidate ranked first in children older than 6 years and referred 3.5 times more often to males compared to females. If age- and sex-specific exposure was considered, more ADR reports for methylphenidate referred to children 4-6 years and females 13-17 years. Drugs for the treatment of nervous system disorders ranked first among "off-label" ADR reports. CONCLUSIONS: Our analysis underlines the importance of putting the number of ADR reports of a drug in context with its prescriptions. Additionally, differences in age- and sex-stratified analysis were observed which may be associated with age- and sex-specific diseases and, thus, drug exposure. The drugs most frequently included in "off-label" ADR reports differed from those most often used according to literature. |
|---|
| ジャーナル名 | BMC pharmacology & toxicology |
|---|
| Pubmed追加日 | 2021/10/9 |
|---|
| 投稿者 | Dubrall, Diana; Leitzen, Sarah; Toni, Irmgard; Stingl, Julia; Schulz, M; Schmid, Matthias; Neubert, Antje; Sachs, Bernhardt |
|---|
| 組織名 | Institute for Medical Biometry, Informatics and Epidemiology, University Hospital;of Bonn, Bonn, Germany. Diana.dubrall@bfarm.de.;Research Division, Federal Institute for Drugs and Medical Devices, Bonn,;Germany. Diana.dubrall@bfarm.de.;Germany.;Department of Physics, Chemistry and Pharmacy, University of Southern Denmark,;Odense, Denmark.;Department of Paediatrics and Adolescent Medicine, University Hospital Erlangen,;Erlangen, Germany.;Institute of Clinical Pharmacology, University Hospital of the RWTH Aachen,;Aachen, Germany.;Central Research Institute of Ambulatory Health Care in Germany, Berlin, Germany.;of Bonn, Bonn, Germany.;Department for Dermatology and Allergy, University Hospital Aachen, Aachen, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34620231/ |
|---|
